Company attributes
Other attributes
Chimera Bioengineering is a biotechnology company developing cell therapies to treat cancer that is headquartered in South San Francisco, California and was founded in 2015 by Ben Wang, Christina Smolke, and Gusti Zeiner.
The company is researching gene therapeutics based on Chimeric antigen receptor T-cells (CAR-Ts). These reprogrammed immune cells are hot-wired to circumvent immune-evasion. CAR-Ts against leukemias and lymphomas have shown transformative results for patients unresponsive to standard therapy. However limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence have stopped these therapies making a wider impact on cancer patients.
Chimera Bioengineering is researching methods to solve the challenges of CAR-Ts with RNA-based gene regulatory systems which allow them to re-program the immune system. They design CAR-T behavior to minimize toxicity, maximize efficacy and extend persistence.
On November 16, 2016 Chimera Bioengineering raised an undisclosed amount of venture capital funding from The Angel's Forum and Sand Hill Angels.
On August 25, 2017 Chimera Bioengineering completed its seed funding round with an undisclosed amount of funding from Kairos Venture Investments.
On May 28, 2019 Chimera Bioengineering raised $16.3M in a venture round of funding.
